An open study of dehydroepiandrosterone in systemic lupus erythematosus

Vollenhoven, R F van; Engleman, Edgar G.; McGuire, James

doi:10.1002/art.1780370906

Cited by 154 publications

(82 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is possible that a regimen providing even greater benefit could be established. DHEA is a naturally abundant adrenal steroid, and high exogenous doses have been well tolerated in various human studies (2). Mechanistically, we believe that high doses of DHEA may be reducing the secretion of macrophage TNFa, thus reducing the severity of the initial inflammatory response.…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Reduction in the incidence and severity of collagen‐induced arthritis in DBA/1 mice, using exogenous dehydroepiandrosterone

Williams

Jones

Rademacher

1997

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. This study examined the effect of exogenous dehydroepiandrosterone (DHEA) on the onset, incidence, and severity of collagen-induced arthritis (CIA).Methods. DHEA was administered subcutaneously prior to arthritis induction in DBN1 mice, and the severity of the subsequent arthritis was monitored. Serum levels of total IgG and IgG isotype-specific anti-murine type I1 collagen were measured.Results. Repeated administration of DHEA during arthritis induction delayed the onset and decreased the severity of arthritis in male and female DBN1 mice. DHEA failed to have an observable effect on established arthritis. IgG isotype autoantibody levels were found to be decreased in the sera of DHEA-treated mice.Conclusion. Administration of exogenous DHEA offered protection against the development of CIA. These data support the results of human studies in which low DHEA levels have been identified as a potential risk factor for the development of rheumatoid arthritis. These findings also highlight DHEA as a potential therapy worthy of further investigation. dition in New Zealand black X New Zealand white mice (for review, see ref.

show abstract

Section: Discussionmentioning

confidence: 90%

“…1). DHEA has also been shown to have therapeutic potential in the treatment of SLE (2). Low serum DHEA sulfate (DHEAS) levels have also been proposed to represent a significant risk factor for the development of rheumatoid arthritis (RA) in the female population ( 3 ) .…”

mentioning

confidence: 99%

Reduction in the incidence and severity of collagen‐induced arthritis in DBA/1 mice, using exogenous dehydroepiandrosterone

Williams

Jones

Rademacher

1997

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…In open-label and placebo-controlled studies, Van Vollenhoven et al (21,22) reported that SLE patients receiving oral prasterone 200 mg/day had improvement in a number of outcome variables, including reduction of steroid dosages, the number of disease flares, and global assessments of disease activity (21,22). In an initial phase II/III trial comparing placebo with 100 and 200 mg/day of prasterone, it was demonstrated that 200 mg/day of prasterone allowed a sustained reduction in the glucocorticoid dosage (23).…”

mentioning

confidence: 99%

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus

Petri¹,

Mease²,

Merrill³

et al. 2004

Arthritis & Rheumatism

134

View full text Add to dashboard Cite

Objective. To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms.Methods. Women with active SLE were treated with prasterone 200 mg/day plus standard SLE treatments or with placebo plus standard SLE treatments for up to 12 months in this randomized, double-blind investigation conducted at 27 centers. Standard SLE treatments included prednisone (<10 mg/day), antimalarials, and immunosuppressive agents; dosages were required to be stable for >6 weeks prior to enrollment and remain unchanged during protocol treatment. Re-

show abstract

“…In humans, many chronic inflammatory diseases are associated with lower serum levels of DHEA or DHEAS (21). Therapy with DHEA has shown benefit in some patients with systemic lupus erythematosus (22) and HIV infection (23). Our previous study has shown that the addition of DHEA to in vitro cultures inhibits the development of Th1 cells (24).…”

mentioning

confidence: 99%

Administration of Dehydroepiandrosterone Suppresses Experimental Allergic Encephalomyelitis in SJL/J Mice

Khalil

Subramaniam

2001

The Journal of Immunology

View full text Add to dashboard Cite

Experimental allergic encephalomyelitis (EAE) is a Th1-mediated inflammatory demyelinating disease in the CNS, an animal model of multiple sclerosis. We have examined the effect of dehydroepiandrosterone (DHEA) on the development of EAE in mice. The addition of DHEA to cultures of myelin basic protein-primed splenocytes resulted in a significant decrease in T cell proliferation and secretion of (pro)inflammatory cytokines (IFN-γ, IL-12 p40, and TNF-α) and NO in response to myelin basic protein. These effects were associated with a decrease in activation and translocation of NF-κB. In vivo administration of DHEA significantly reduced the severity and incidence of acute EAE, along with a decrease in demyelination/inflammation and expressions of (pro)inflammatory cytokines in the CNS. These studies suggest that DHEA has potent anti-inflammatory properties, which at least are in part mediated by its inhibition of NF-κB activation.

show abstract

An open study of dehydroepiandrosterone in systemic lupus erythematosus

Cited by 154 publications

References 19 publications

Reduction in the incidence and severity of collagen‐induced arthritis in DBA/1 mice, using exogenous dehydroepiandrosterone

Reduction in the incidence and severity of collagen‐induced arthritis in DBA/1 mice, using exogenous dehydroepiandrosterone

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus

Administration of Dehydroepiandrosterone Suppresses Experimental Allergic Encephalomyelitis in SJL/J Mice

Contact Info

Product

Resources

About